This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
For more than 25 years, life science companies, law firms, and regulatory agencies around the globe have turned to CRA’s life sciences consultants when they need clarity and solutions to the industry’s most complex issues. Clients value our deep industry knowledge, rigorous analytic techniques, and decades of hands-on experience spanning thousands of successful engagements.
In Part 3 of this series, RADAR data on orphan-drug pricing in Germany revealed a significant increase in manufacturer-set list prices for new orphan drugs...
CRA Life Sciences experts Tim Wilsdon, Michele Pistollato, Antun Sablek, and Qinyi Wang contributed to a research article
CRA is a proud sponsor of the conference focusing on the intersection of intellectual property and the biopharmaceutical industry, and will explore the law,...
CRA is a proud sponsor of the the largest and most established orphan drug & rare disease meeting of its kind across the globe. From cell and gene therapy,...
Ryan Lawlor presents the session titled “Prioritising Alzheimer’s Disease in Europe: Next steps for Policy Action.” Tim Wilsdon moderates the panel discussion...
Annabelle Fowler presents the CRA paper titled “An Analysis of Medicaid CPI Rebates and the Sustainability of U.S. Generic Markets.” Ashutosh Mishra presents...
